Movatterモバイル変換

LY305

From Wikipedia, the free encyclopedia

Chemical compound

Pharmaceutical compound

LY305
Legal status

Legal status	Investigational
Identifiers
IUPAC name 2-Chloro-4-[[(1R,2R)-2-hydroxy-2-methylcyclopentyl]amino]-3-methylbenzonitrile
CAS Number	1430230-83-3
PubChemCID	71543393
ChemSpider	58921204
ChEMBL	ChEMBL3764185
Chemical and physical data
Formula	C₁₄H₁₇ClN₂O₂
Molar mass	280.75 g·mol⁻¹
3D model (JSmol)	Interactive image
SMILES CC1=C(C=CC(=C1Cl)C#N)N[C@@H]2CCC[C@@]2(C)O
InChI InChI=1S/C14H17ClN2O/c1-9-11(6-5-10(8-16)13(9)15)17-12-4-3-7-14(12,2)18/h5-6,12,17-18H,3-4,7H2,1-2H3/t12-,14-/m1/s1 Key:CXFSVKGROITHRY-TZMCWYRMSA-N

LY305 is atransdermally bioavailableselective androgen receptor modulator (SARM) developed byEli Lilly for the treatment ofosteoporosis in men. Its chemical structure includesN-arylhydroxyalkyl. A phase one trial found promising results.^[1]^[2]^[3]

^Krishnan, V.; Patel, N. J.; Mackrell, J. G.; Sweetana, S. A.; Bullock, H.; Ma, Y. L.; Waterhouse, T. H.; Yaden, B. C.; Henck, J.; Zeng, Q. Q.; Gavardinas, K.; Jadhav, P.; Saeed, A.; Garcia-Losada, P.; Robins, D. A.; Benson, C. T. (2018)."Development of a selective androgen receptor modulator for transdermal use in hypogonadal patients".Andrology.6 (3):455–464.doi:10.1111/andr.12479.
^Christiansen, Andrew R.; Lipshultz, Larry I.; Hotaling, James M.; Pastuszak, Alexander W. (March 2020)."Selective androgen receptor modulators: the future of androgen therapy?".Translational Andrology and Urology.9 (Suppl 2):S135 –S148.doi:10.21037/tau.2019.11.02.ISSN 2223-4683.PMC 7108998.PMID 32257854.
^Mohler ML, Sikdar A, Ponnusamy S, Hwang DJ, He Y, Miller DD, Narayanan R. An Overview of Next-Generation Androgen Receptor-Targeted Therapeutics in Development for the Treatment of Prostate Cancer.Int J Mol Sci. 2021 Feb 20;22(4):2124.doi:10.3390/ijms22042124PMID 33672769

Hidden categories: